Statin Use in HIV Reduces Mortality
Author Information
Author(s): Richard D. Moore, John G. Bartlett, Joel E. Gallant
Primary Institution: Johns Hopkins University School of Medicine
Hypothesis
Does the use of statins in HIV-infected patients receiving HAART reduce mortality?
Conclusion
Statin use was associated with a significantly lower hazard of dying in HIV-infected patients effectively treated with HAART.
Supporting Evidence
- Statin use was associated with a relative hazard of 0.33 after adjusting for various clinical factors.
- Out of 1538 patients, 238 received statins, with 85 deaths recorded.
- Malignancy, non-AIDS-defining infections, and liver failure were prominent causes of death.
Takeaway
Taking statins might help people with HIV live longer when they are on treatment.
Methodology
Cox proportional hazards regression was used to assess the association of statin use with mortality in HIV-infected patients who achieved virologic suppression.
Potential Biases
Statins may have been selectively prescribed to patients perceived to be at lower risk of dying.
Limitations
The observational nature of the study may introduce selection bias, and the small number of deaths among statin users limits the analysis of specific statin types.
Participant Demographics
The sample included 1538 HIV-infected patients, with 15.5% receiving statins; statin users were older, more likely to be white, and had higher CD4+ counts.
Statistical Information
P-Value
0.009
Confidence Interval
0.14, 0.76
Statistical Significance
p=0.009
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website